Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Phenotype-based pain management for chronic post-treatment pain after head and neck cancer

Official title: Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study

Run by Shaukat Khanum Memorial Cancer Hospital & Research Centre · NCT07919457 · Data updated 2026-11-12

We’re testing a personalized pain plan to see if tailoring treatment to a patient’s pain type can reduce chronic pain in adults who completed head and neck cancer treatment.

More Chemotherapy-induced Peripheral Neuropathy trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorShaukat Khanum Memorial Cancer Hospital & Research Centre
Academic / other
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedJuly 16, 2026
Main results expectedJanuary 31, 2027
Study endsFebruary 28, 2027
Registry record updatedNovember 5, 2026
Trial IDNCT07919457 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with prior curative treatment for head and neck cancer and ongoing chronic post-treatment pain without evidence of recurrent disease.

Probably not a fit

Patients with pain that does not respond to phenotype-driven strategies or those who experience intolerable side effects may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot Phase 2 interventional trial explores a phenotype-driven approach to managing chronic post-treatment pain in adults who have finished curative therapy for head and neck cancer. Participants undergo three visits over one month, complete pain and mood questionnaires, and receive a pain-phenotype assessment to guide a tailored treatment plan that may include medications, trigger point injections, or nerve blocks. The study aims to determine whether the approach can reduce average pain by at least 75% after four weeks and to evaluate safety, with a limit on treatment-related dropouts. Eligibility includes adults with a history of curative treatment and persistent chronic pain, and exclusions cover active disease, infection, wound issues, or cognitive impairment affecting questionnaire completion.

Why it matters

Potential benefit: If successful, participants may experience significant reductions in chronic pain and improved function.

How similar studies have gone: Previous work has shown that phenotype-guided pain management can be beneficial in chronic pain, but this specific approach in post-treatment head and neck cancer pain is exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (≥18 years) with history of curative treatment for head and neck cancer
* Chronic post-treatment pain disorder
* Absence of clinical and radiological evidence of recurrent disease
* Ability to provide informed consent

Exclusion Criteria:

* Active disease recurrence or metastasis
* Persistent mucositis, oral infection, or hardware failure at the treatment site
* Surgical wound dehiscence
* Cognitive impairment that limits the ability to complete study questionnaires

Where it's running

  • Shaukat Khanum Memorial Cancer Hospital & Research Centre
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.